Israeli-based Phytotech Therapeutics Ltd Division Of HarvestPhytotech has developed advanced oral delivery formulations for cannabinoid-based prescription drugs and holds an exclusive worldwide licensing agreement with Yissum Research Development Company, the commercial arm of the University of Jerusalem, for a proprietary lipid nanotechnology. With the acquisition, Harvest Ones wholly-owned subsidiary Satipharm will gain access to advanced patents in favourable jurisdictions that can be used for further R&D and product development to aggressively pursue the rapidly evolving cannabis oils market. PTL was also responsible for administrating the successful clinical trials using Satipharms proprietary capsules. The Phase 1 clinical trials demonstrated the safety and high performance of the oral capsule technology, including the effective delivery profile of cannabidiol (CBD), while Phase 2 clinical trials were completed in 2017, returning favourable results in the treatment of pediatric epilepsy.